OncoMatch/Clinical Trials/NCT06538857
CEB-01 in Locally Resectable Pancreatic Cancer
Is NCT06538857 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies CEB-01 for pancreatic carcinoma.
Treatment: CEB-01 — The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: UGT1A1 homozygous
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
haemoglobin (Hb) ≥10 g/dL (with preoperative transfusion), platelets ≥80,000/mm3 with intraoperative transfusion, WBC ≥3,000/mm3, neutrophil count ≥1,500/mm3
Kidney function
creatinine ≤2 mg/dl or creatinine clearance ≥ 60 ml/min/1.73 m2
Liver function
ALT and AST ≤ 4x ULN; recommended serum bilirubin ≤ 10 mg/dl (or equivalent value in μmol/L units); preoperative biliary drainage per clinical practice
Cardiac function
cardiac function as defined by biochemical and haematological parameters
Normal renal function as defined by biochemical parameters as follows: creatinine ≤2 mg/dl or creatinine clearance ≥ 60 ml/min/1.73 m2. Haematological and cardiac function as defined by biochemical and haematological parameters as follows: haemoglobin (Hb) ≥10 g/dL (with preoperative transfusion), platelets ≥80.000/mm3 with intraoperative transfusion, white blood cells (WBC) ≥3.000/mm3, neutrophil count ≥1.500/mm3. Liver function as defined by biochemical parameters as follows: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 4 times the upper limit of normality [ULN]. Recommended serum bilirubin for eligibility is bilirubin ≤ 10 mg/dl (or equivalent value in μmol/L units).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06538857 currently recruiting?
Yes, this trial is currently recruiting patients.
Are patients with UGT1A1 alterations eligible?
No. UGT1A1 homozygous is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages